OncLive TV

Aaron Goodman, MD, discusses factors that have contributed to the lack of treatment development in peripheral T-cell lymphoma.

Andrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Richard L. Shapiro, MD, discusses the surgical management of advanced-stage melanoma.

C. Parker Gibbs Jr, MD, discusses the lack of treatment options for patients with soft tissue and bone sarcomas.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, discusses the importance of developing biomarkers of response to the combination of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer.

Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses remaining challenges with the advancing treatments in prostate cancer.

Petros Grivas, MD, discusses comparisons between ATM and BRCA1/2 mutations in metastatic castration-resistant prostate cancer.

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Jonathan W. Goldman, MD, discusses targeted therapy options for patients with EGFR-, ALK-, and ROS1-mutated non–small cell lung cancer.

Brian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Richard T. Penson, MD, MRCP, associate professor of medicine, Harvard Medical School, and clinical director of Medical Gynecologic Oncology, in the Department of Medicine, Massachusetts General Hospital, discusses the eligibility criteria for PARP inhibitors in advanced ovarian cancer.

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses ongoing research regarding neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian cancer.

Robert M. Wenham, MD, gynecologic oncologist and chair of the Gynecologic Oncology Program at Moffitt Cancer Center, discusses data with intraperitoneal (IP) chemotherapy, dose-dense chemotherapy, and intravenous (IV) chemotherapy in patients with advanced ovarian cancer.

Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Aaron Gerds, MD, discusses results of a phase II trial examining the safety and efficacy of luspatercept as a treatment for anemia in patients with myelofibrosis.

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Larry J. Copeland, MD, discusses the prevalence of ovarian cancer in the United States.

Van K. Morris, MD, discusses the recent progress made in the treatment of patients with BRAF-mutated metastatic colorectal cancer.